[Skip to Content]
[Skip to Content Landing]
December 6, 1965

Preliminary Evaluation of Cycloguanil Pamoate in Dermal Leishmaniasis

Author Affiliations

From the Louisiana State University International Center for Medical Research and Training and the Hospital Nacional de Niños, San José, Costa Rica.

JAMA. 1965;194(10):1142-1144. doi:10.1001/jama.1965.03090230110039

SOME REGRESSION of early lesions of dermal leishmaniasis has been observed by one of the authors (A.P.C.) in malaria patients treated orally with chloroguanide hydrochloride. The extent of improvement in the leishmanial lesions was not great, however, possibly because of the short duration of chloroguanide hydrochloride administration. The antimalarial activity of chloroguanide hydrochloride in man is due mainly to a dihydrotriazine metabolite of the drug.1-5 Cycloguanil pamoate (CI-501; Camolar)6 is a poorly water-soluble salt of this dihydrotriazine. An intramuscular dose of cycloguanil pamoate acts as a repository antimalarial drug in animals6,7 and man.8-11 Therefore, it seemed worthwhile to evaluate the efficacy of cycloguanil pamoate in patients with dermal leishmaniasis, caused by Leishmania braziliensis. This preliminary report gives the results obtained with cycloguanil pamoate in 30 such Costa Rican patients.

Materials and Methods  The patients who received treatment ranged in age from 7 months to 60 years,

First Page Preview View Large
First page PDF preview
First page PDF preview